The primary endpoint of the study was patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201. N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a crucial store of nitric oxide bioactivity in the human airway.
Charles Scoggin, chairman of N30 Pharma, said: “We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to human subjects is the first step.”